Bayer: Very successful start to 2014
- Details
- Category: Bayer
Sales of the Bayer Group advanced by 2.8 percent in the first quarter of 2014 to EUR 10,555 million (Q1 2013: EUR 10,266 million). Adjusted for currency and portfolio effects (Fx & portfolio adj.), business expanded by 8.4 percent. EBIT rose by 18.4 percent to EUR 2,096 million (Q1 2013: EUR 1,771 million) after net special items of plus EUR 7 million (Q1 2013: minus EUR 45 million). EBIT before special items increased by 15.0 percent to EUR 2,089 million (Q1 2013: EUR 1,816 million).
Pfizer Confirms prior discussions with AstraZeneca
- Details
- Category: Pfizer
Pfizer Inc. confirms that it previously submitted a preliminary, non-binding indication of interest to the board of directors of AstraZeneca in January 2014 regarding a possible merger transaction. After limited high-level discussions, AstraZeneca declined to pursue negotiations.
Novartis delivered solid sales and profit growth in the first quarter of 2014
- Details
- Category: Novartis
Subsequent to the quarter end, Novartis announced that it had reached definitive agreements with GlaxoSmithKline plc (GSK) and Eli Lilly and Company (Lilly) on a set of transactions. In an inter-conditional transaction with GSK: (1) Novartis agreed to acquire GSK oncology products and to become GSK's preferred commercialization partner for its oncology pipeline for a USD 14.5 billion payment and up to USD 1.5 billion contingent on a development milestone;
Bristol-Myers Squibb ranks first on 2014 Best Corporate Citizens List
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) has been ranked No. 1 on Corporate Responsibility magazine's 2014 list of the 100 Best Corporate Citizens, a leading benchmark for socially responsible investors and other stakeholders. Bristol-Myers Squibb is the only company to achieve the No. 1 ranking three times, including 2009 and 2012, and has ranked among the top 10 each of the last six years.
Novartis announces portfolio transformation
- Details
- Category: Novartis
Novartis has reached a definitive agreement with GlaxoSmithKline plc (GSK) to exchange certain assets, building global leadership in key segments and focusing the company's portfolio. Under the agreement, Novartis would strengthen the company's innovative pharmaceuticals business by acquiring GSK oncology products, and would divest Vaccines (excluding flu) to them.
Abbott reports first-quarter 2014 results
- Details
- Category: Abbott
Abbott (NYSE: ABT) has announced financial results for the first quarter ended March 31, 2014. First-quarter 2014 worldwide sales of $5.2 billion increased 0.5 percent on an operational basis and decreased 2.5 percent on a reported basis, including an unfavorable 3.0 percent effect of foreign exchange.
Roche with good start in 2014
- Details
- Category: Roche
Group sales rose 5% in the first quarter, driven by demand for cancer medicines (in particular the HER2 breast cancer franchise, Avastin and MabThera/Rituxan), as well as Actemra/RoActemra for rheumatoid arthritis. Sales of Xeloda, a chemotherapy drug, were lower as the product is now off patent and faces generic competition in the United States and Europe.
More Pharma News ...
- Abbott completes enrollment of Absorb™ randomized clinical trials in the United States, Japan and China
- Novartis and Malaria No More provide two million antimalarial treatments to children in Zambia
- Merck Serono enters into research agreement with Pfizer and Broad Institute
- Bayer HealthCare to significantly increase production capacity in China
- AstraZeneca and MRC enter strategic collaboration
- Novo Nordisk launches 'Cities Changing Diabetes' to fight urban diabetes
- Where do you start when developing a new medicine?